{"id":"https://openalex.org/W4367307414","doi":"https://doi.org/10.5055/jom.2023.0781","title":"Tramadol utilization among patients with higher risk of adverse drug events: A claims analysis of commercially insured and Medicare Advantage members","display_name":"Tramadol utilization among patients with higher risk of adverse drug events: A claims analysis of commercially insured and Medicare Advantage members","publication_year":2023,"publication_date":"2023-04-19","ids":{"openalex":"https://openalex.org/W4367307414","doi":"https://doi.org/10.5055/jom.2023.0781","pmid":"https://pubmed.ncbi.nlm.nih.gov/37145928"},"language":"en","primary_location":{"id":"doi:10.5055/jom.2023.0781","doi":"https://doi.org/10.5055/jom.2023.0781","is_oa":false,"landing_page_url":"https://doi.org/10.5055/jom.2023.0781","pdf_url":null,"source":{"id":"https://openalex.org/S2764961062","display_name":"Journal of Opioid Management","issn_l":"1551-7489","issn":["1551-7489","2375-0146"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Opioid Management","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003758064","display_name":"Eric P. Borrelli","orcid":"https://orcid.org/0000-0002-9941-9893","observed_orcids":["https://orcid.org/0000-0002-9941-9893"]},"institutions":[{"id":"https://openalex.org/I17626003","display_name":"University of Rhode Island","ror":"https://ror.org/013ckk937","country_code":"US","type":"education","lineage":["https://openalex.org/I17626003"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric P. Borrelli, PhD, PharmD, MBA","raw_affiliation_strings":["University of Rhode Island College of Pharmacy, Kingston, Rhode Island. ORCID: https://orcid.org/0000-0002-9941-9893"],"raw_orcid":"https://orcid.org/0000-0002-9941-9893","affiliations":[{"raw_affiliation_string":"University of Rhode Island College of Pharmacy, Kingston, Rhode Island. ORCID: https://orcid.org/0000-0002-9941-9893","institution_ids":["https://openalex.org/I17626003"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019064294","display_name":"Jeffrey P. Bratberg","orcid":"https://orcid.org/0000-0002-2240-5768","observed_orcids":["https://orcid.org/0000-0002-2240-5768"]},"institutions":[{"id":"https://openalex.org/I17626003","display_name":"University of Rhode Island","ror":"https://ror.org/013ckk937","country_code":"US","type":"education","lineage":["https://openalex.org/I17626003"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Bratberg, PharmD, FAPhA","raw_affiliation_strings":["University of Rhode Island College of Pharmacy, Kingston, Rhode Island"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Rhode Island College of Pharmacy, Kingston, Rhode Island","institution_ids":["https://openalex.org/I17626003"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035951170","display_name":"Mary L. Greaney","orcid":"https://orcid.org/0000-0002-5963-920X","observed_orcids":["https://orcid.org/0000-0002-5963-920X"]},"institutions":[{"id":"https://openalex.org/I17626003","display_name":"University of Rhode Island","ror":"https://ror.org/013ckk937","country_code":"US","type":"education","lineage":["https://openalex.org/I17626003"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary L. Greaney, PhD, MPH","raw_affiliation_strings":["University of Rhode Island College of Health Sciences, Kingston, Rhode Island"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Rhode Island College of Health Sciences, Kingston, Rhode Island","institution_ids":["https://openalex.org/I17626003"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087981760","display_name":"Stephen J Kogut","orcid":"https://orcid.org/0000-0001-8298-6245","observed_orcids":["https://orcid.org/0000-0001-8298-6245"]},"institutions":[{"id":"https://openalex.org/I17626003","display_name":"University of Rhode Island","ror":"https://ror.org/013ckk937","country_code":"US","type":"education","lineage":["https://openalex.org/I17626003"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen J. Kogut, PhD, MBA, RPh","raw_affiliation_strings":["University of Rhode Island College of Pharmacy, Kingston, Rhode Island"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Rhode Island College of Pharmacy, Kingston, Rhode Island","institution_ids":["https://openalex.org/I17626003"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I17626003"],"apc_list":null,"apc_paid":null,"fwci":1.0191,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.73963898,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":98},"biblio":{"volume":"19","issue":"3","first_page":"257","last_page":"271"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.6147000193595886,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.6147000193595886,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":0.21899999678134918,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10496","display_name":"Pharmaceutical Practices and Patient Outcomes","score":0.14000000059604645,"subfield":{"id":"https://openalex.org/subfields/2717","display_name":"Geriatrics and Gerontology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tramadol","display_name":"tramadol","score":0.9980000257492065},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8690000176429749},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.8309999704360962},{"id":"https://openalex.org/keywords/cytochrome-p450-inhibitors","display_name":"cytochrome P450 inhibitors","score":0.8960000276565552},{"id":"https://openalex.org/keywords/serotonergic-medications","display_name":"serotonergic medications","score":0.8270000219345093},{"id":"https://openalex.org/keywords/benzodiazepines","display_name":"benzodiazepines","score":0.9710000157356262},{"id":"https://openalex.org/keywords/epilepsy","display_name":"epilepsy","score":0.6499999761581421},{"id":"https://openalex.org/keywords/prescribing-patterns","display_name":"prescribing patterns","score":0.4729999899864197},{"id":"https://openalex.org/keywords/commercially-insured-patients","display_name":"commercially insured patients","score":0.9150000214576721},{"id":"https://openalex.org/keywords/medicare-advantage","display_name":"Medicare Advantage","score":0.7889999747276306},{"id":"https://openalex.org/keywords/opioid-prescribing","display_name":"opioid prescribing","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C2779777798","wikidata":"https://www.wikidata.org/wiki/Q407592","display_name":"Tramadol","level":3,"score":0.9554193019866943},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9540852308273315},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6527017951011658},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.533424973487854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47875848412513733},{"id":"https://openalex.org/C23276603","wikidata":"https://www.wikidata.org/wiki/Q158230","display_name":"Pharmacoepidemiology","level":3,"score":0.4599972665309906},{"id":"https://openalex.org/C142454548","wikidata":"https://www.wikidata.org/wiki/Q7069573","display_name":"Number needed to harm","level":5,"score":0.4490542709827423},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.4421062469482422},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4376836121082306},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.30253076553344727},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.20656314492225647},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.19994902610778809},{"id":"https://openalex.org/C67774102","wikidata":"https://www.wikidata.org/wiki/Q614132","display_name":"Number needed to treat","level":4,"score":0.12934312224388123},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.11451047658920288},{"id":"https://openalex.org/C2780820201","wikidata":"https://www.wikidata.org/wiki/Q173235","display_name":"Analgesic","level":2,"score":0.10685327649116516},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.09205359220504761}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000701","descriptor_name":"Analgesics, Opioid","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003430","descriptor_name":"Cross-Sectional Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007345","descriptor_name":"Insurance Claim Review","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014147","descriptor_name":"Tramadol","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020398","descriptor_name":"Medicare Part C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D064420","descriptor_name":"Drug-Related Side Effects and Adverse Reactions","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.5055/jom.2023.0781","doi":"https://doi.org/10.5055/jom.2023.0781","is_oa":false,"landing_page_url":"https://doi.org/10.5055/jom.2023.0781","pdf_url":null,"source":{"id":"https://openalex.org/S2764961062","display_name":"Journal of Opioid Management","issn_l":"1551-7489","issn":["1551-7489","2375-0146"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Opioid Management","raw_type":"journal-article"},{"id":"pmid:37145928","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37145928","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of opioid management","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2305065649","https://openalex.org/W3131389559","https://openalex.org/W1897495593","https://openalex.org/W6987593525","https://openalex.org/W7100343428","https://openalex.org/W7098537440","https://openalex.org/W4256062298","https://openalex.org/W2110229597","https://openalex.org/W4391540258","https://openalex.org/W2324676901"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"assess":[2],"prescribing":[3],"of":[4,13,20,41,111,175,192,198,213,217,258,264],"tramadol":[5,34,64,84,112,179,209,231,265],"among":[6,87],"patients":[7,37,88,124,176,193,205,229],"with":[8,38,60,89,108,125,261],"contraindications":[9,90],"and":[10,23,157],"higher":[11,39],"risks":[12,219],"adverse":[14,42,95],"events":[15],"in":[16,36,113,203,210,227,266],"a":[17,30,67,154,166,182,233],"large":[18],"population":[19],"commercially":[21],"insured":[22],"Medicare":[24],"Advantage":[25],"members.":[26],"DESIGN:":[27],"We":[28,80,97],"performed":[29],"cross-sectional":[31],"analysis":[32],"evaluating":[33],"utilization":[35],"risk":[40,92],"outcomes.":[43,96],"SETTING:":[44],"This":[45],"study":[46,75],"utilized":[47],"2016-2017":[48],"data":[49],"from":[50],"the":[51,74,109,196,211,256,262],"Optum":[52],"Clinformatics":[53],"Data":[54],"Mart.":[55],"PATIENTS":[56],"AND":[57],"PARTICIPANTS:":[58],"Patients":[59],"at":[61,126,214],"least":[62,127,215],"one":[63,128,202,216,226],"prescription":[65,129],"without":[66],"cancer":[68],"or":[69,91,103,238],"sickle":[70],"cell":[71],"diagnosis":[72],"during":[73],"period.":[76],"MAIN":[77],"OUTCOME":[78],"MEASURES:":[79],"first":[81],"determined":[82,99],"if":[83,100],"was":[85],"prescribed":[86,230],"factors":[93,105],"for":[94,130,240],"then":[98],"patient":[101],"demographic":[102],"clinical":[104],"were":[106,194],"associated":[107,260],"use":[110,263],"these":[114,218,247,267],"higher-risk":[115],"scenarios":[116],"using":[117],"multivariable":[118],"logistic":[119],"regression":[120],"models.":[121],"RESULTS:":[122],"Among":[123],"tramadol,":[131],"19.66":[132],"percent":[133,135,147,149,159,161,170,172,187,189,221],"(99":[134,148,160,171,188,220],"CI:":[136,150,162,173,190,222],"19.57-19.75)":[137],"concurrently":[138,152,164],"received":[139,153,165,178,208],"an":[140],"interacting":[141],"cytochrome":[142],"P450":[143],"isoenzyme":[144],"medication,":[145,156],"19.24":[146],"19.15-19.33)":[151],"serotonergic":[155],"7.93":[158],"7.88-8.00)":[163],"benzodiazepine.":[167],"Additionally,":[168],"1.59":[169],"1.56-1.61)":[174],"who":[177],"also":[180],"had":[181,232],"seizure":[183],"disorder,":[184],"while":[185],"0.55":[186],"0.53-0.56)":[191],"under":[195],"age":[197],"18.":[199],"Overall,":[200],"nearly":[201],"three":[204,228],"(31.17":[206],"percent)":[207],"presence":[212],"31.06-31.27).":[223],"CONCLUSION:":[224],"Almost":[225],"clinically":[234],"significant":[235],"drug":[236],"interaction":[237],"contraindication":[239],"use,":[241],"suggesting":[242],"that":[243],"prescribers":[244],"often":[245],"disregard":[246],"concerns.":[248],"Real-world":[249],"studies":[250],"are":[251],"needed":[252],"to":[253],"better":[254],"understand":[255],"likelihood":[257],"harms":[259],"contexts.":[268]},"counts_by_year":[{"year":2025,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-04-29T00:00:00"}